Association of benign prostatic hyperplasia (BPH) with the metabolic syndrome (MS) and its components

Abstract

Aim:

To determine whether the metabolic syndrome (MS) or its individual components is associated with radiologically determined prostate volume: an objective measure of benign prostatic hyperplasia (BPH).

Methods:

Between January 2008 and December 2009, a case–control study was conducted among 200 males aged over 50 years, attending an urology clinic, with patients diagnosed as having BPH being taken as cases (Group 1), while healthy volunteers were taken as a control group from a routine health camp organized by the Dept. of Urology (Group 2). The prostate volume was determined using ultrasonography, whereas the MS was assessed using the predefined criteria from the National Cholesterol Education Programme–Adult Treatment Panel-III (NCEP–ATP III). Before a physician conducted a digital rectal examination (DRE) on a subject, a blood sample was obtained for serum prostate specific antigen (PSA), fasting blood glucose (FBG), tryglyceride (TG) and high density lipoprotein (HDL) determination. A body mass index (BMI) greater than 25 kg/m² was classified as obese (this cut-off is used for Asians). Waist-to-hip ratio (WHR) was calculated from waist and hip circumferences and was categorized as greater than or equal to 0.90 (score = 1) or as less than 0.90 (score = 2) for defining obesity.

Result:

Two hundred men enrolled in the study (mean age = 65.09 years; range 50–80), of which 85 were diagnosed as having BPH with lower urinary tract symptoms (LUTS: Group 1) and 115 were healthy volunteers from the health camp (Group 2). Comparing both groups the WHR (P = 0.001) and TG levels (P = 0.002) were found to be significantly increased in BPH patients. However, HDL (P = 0.0001) was significantly decreased in BPH patients. Increased WHR, increased TG and decreased HDL were found to be associated with increased incidence of BPH. Twelve BPH patients had all three criteria of the MS.

Conclusion:

This pilot study showed that higher TG levels, a high WHR and lower HDL levels were associated with BPH patients in north Indian men. Very few men had both BPH and the MS, so the MS can act as a borderline risk factor for BPH. Individual factors of the MS may also be associated with increased risk of BPH.

Get full access to this article

View all access options for this article.

References

Gupta

, Gupta

, Pavuk

, Roehrborn

C.G.

Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology, 2006; 68(6):1198–1205.

Lee

, Min

H.G.

, Choi

S.H.

, Kim

Y.J.

, Oh

S.W.

, Kim

Y.J.

, et al. Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring), 2006; 14:172–179.

Parsons

J.K.

, Carter

H.B.

, Partin

A.W.

, Windham

B.G.

, Metter

E.J.

, Ferrucci

, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab, 2006; 91:2562–2568.

Rohrmann

, Smit

, Giovannucci

, Platz

E.A.

Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol, 2004; 159:390–397.

Zucchetto

, Tavani

, Dal Maso

, Gallus

, Negri

, Talamini

, et al. History of weight and obesity through life and risk of benign prostatic hyperplasia. Int J Obes (Lond), 2005; 29:798–803.

International Consensus Committee. Recommendations of the International Consensus Committee 1993. In: Cockett

ATK

, Khoury

, Aso

, Chatelain

, Denis

, Griffiths

, et al., editors. Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey, Channel Islands: Scientific Communication International; 1993. pp 556–64.

Barry

M.J.

, Fowler

F.J.

Jr. , O’Leary

M.P.

, Bruskewitz

R.C.

, Holtgrewe

H.L.

, Mebust

W.K.

, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol, 1992; 148(5):1549–1557.

Parsons

J.K.

, Carter

H.B.

, Partin

A.W.

, Windham

B.G.

, Metter

E.J.

, Ferrucci

, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab, 2006; 91(7):2562–2568.

Gogia

, Agarwal

P.K.

Metabolic syndrome. Indian Med J Sci, 2006; 60:72–81.

10.

Ford

E.S.

, Giles

W.H.

, Dietz

W.H.

Prevalence of metabolic syndrome among US adults –findings from the third National Health and Nutrition Examination Survey. JAMA, 2002; 287:356–359.

11.

Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001; 285(19):2846–97.

12.

Hautanen

Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes Relat Metab Disord, 2000; 24(Suppl 2):S64–S70.

13.

Shibata

, Ito

, Suzuki

, Nakano

, Fukabori

, Suzuki

, et al. Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate, 2000; 42:45–55.

14.

Giovannucci

, Rimm

E.B.

, Chute

C.G.

, Kawachi

, Colditz

G.A.

, Stampfer

M.J.

, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol, 1994; 140:989–1002.

15.

Glynn

R.J.

, Campion

E.W.

, Bouchard

G.R.

, Silbert

J.E.

The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol, 1985; 121:78–90.

16.

Lee

, Min

H.G.

, Choi

S.H.

, Kim

Y.J.

, Oh

S.W.

, Kim

Y.J.

, et al. Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring), 2006; 14(1):172–179.

17.

Matsuda

, Abe

, Suda

[Relation between benign prostatic hyperplasia and obesity and estrogen]. Rinsho Byori, 2004; 52:291–294 [In Japanese].

18.

Joseph

M.A.

, Wei

J.T.

, Harlow

S.D.

, Cooney

K.A.

, Dunn

R.L.

, Jaffe

C.A.

, et al. Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate, 2002; 53:322–329.

19.

Parsons

J.K.

Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol, 2007; 178(2):395–401.

20.

Flegal

K.M.

, Carroll

M.D.

, Ogden

C.L.

, Johnson

C.L.

Prevalence and trends in obesity among US adults, 1999-2000. JAMA, 2002; 288:1723–1727.

21.

Daviglus

M.L.

, Liu

, Yan

L.L.

, Pirzada

, Manheim

, Manning

, et al. Relation of body mass index in young adulthood and middle age to Medicare expenditures in older age. JAMA, 2004; 292:2743–2749.

22.

Signorello

L.B.

, Tzonou

, Lagiou

, Samoli

, Zavitsanos

, Trichopoulos

The epidemiology of benign prostatic hyperplasia. A study in Greece. BJU Int, 1999; 84:286–291.

23.

Dahle

S.E.

, Chokkalingam

A.P.

, Gao

Y.T.

, Deng

, Stanczyk

F.Z.

, Hsing

A.W.

Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol, 2002; 168:599–604.

24.

Haffner

, Taegtmeyer

. Epidemic obesity and the metabolic syndrome. Circulation, 203: 108:1541–5.

25.

Furukawa

, Fujita

, Shimabukuro

, Iwaki

, Yamada

, Nakajima

, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest, 2004; 114:1752–1761.

26.

Nelson

W.G.

, De Marzo

A.M.

, Isaacs

W.B.

Prostate cancer. N Engl J Med, 2003; 349:366–381.

27.

Suzuki

, Platz

E.A.

, Kawachi

, Willett

W.C.

, Giovannucci

Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr, 2002; 75:689–697.

28.

Khandwala

H.M.

, McCutcheon

I.E.

, Flyvbjerg

, Friend

K.E.

The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev, 2000; 21:215–244.

29.

Wang

, Bergh

, Damber

J.E.

Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate, 2004; 61:60–72.

30.

Nickel

J.C.

, Downey

, Young

, Boag

Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int, 1999; 84:976–981.

31.

Anim

J.T.

, Udo

, John

Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem, 1998; 100:439–449.

32.

Di Silverio

, Gentile

, De Matteis

, Mariotti

, Giuseppe

, Luigi

P.A.

, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol, 2003; 43:164–175.

33.

Hammarsten

, Hogstedt

, Holthuis

, Mellstrom

Components of the metabolic syndrome – risk factors for the development of benign prostatic hyperplasia. Prostate cancer Prostatic Dis, 1998; 1:157–162.

34.

Nandeesha

, Koner

B.C.

, Dorairajan

L.N.

, Sen

S.K.

Hyperinsulinemia and dyslipidemia in non diabetic benign prostate hyperplasia. Clin Chim Acta, 2006; 370(1–2):89–93.

35.

Parsons

J.K.

, Bergstrom

, Barrett-Connor

Lipids, lipoproteins, and risk of benign prostatic hyperplasia in community dwelling men. BJU Int, 2008; 101(3):313–318.

36.

Mitropoulos

, Ploumidou

, Kyroudi-Voulgari

, Perea

, Kittas

, Karayannacos

Hypercholesterol diet (HD) alters serum lipid profile and ventral prostate structure in rats. Eur Urol Suppl., 2003; 2(1):20 [Abstract].

37.

Calle

E.E.

, Kaaks

Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer, 2004; 4:579–591.

38.

Hong

, Kwon

, Yoon

, Lee

, Kim

H.H.

, et al. Risk factors for benign prostatic hyperplasia in South Korean men. Urol Int, 2006; 76(1):11–19.

39.

Meigs

J.B.

, Mohr

, Barry

M.J.

, McNaughton Collins

, McKinley

J.B.

Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol, 2001; 54:935–944.

Association of benign prostatic hyperplasia (BPH) with the metabolic syndrome (MS) and its components – ‘a growing dilemma’

Abstract

Abstract

Aim:

Methods:

Result:

Conclusion:

Get full access to this article

References